2-(4-Chloro-phenoxy)-1-piperidin-1-yl-ethanone | 39489-65-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(4-Chloro-phenoxy)-1-piperidin-1-yl-ethanone
• 英文别名: 1-[(4-Chlorophenoxy)acetyl]piperidine；2-(4-chlorophenoxy)-1-piperidin-1-ylethanone
• CAS: 39489-65-1
• 化学式: C₁₃H₁₆ClNO₂
• mdl: MFCD00816018
• 分子量: 253.729
• InChiKey: XQIAIYFPKZGUCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-Chloro-phenoxy)-1-piperidin-1-yl-ethanone 在 2-氟吡啶 、 三氟甲磺酸酐 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 1-(5-chloro-1-benzofuran-3-yl)piperidine
  参考文献：
  名称：

  Mild and Efficient Tf2O-Mediated Synthesis of 3-Amino-1-benzofurans

  摘要：

  A mild and efficient procedure has been developed for the synthesis of 3-amino-1-benzofurans by intramolecular cyclization of the corresponding N,N-disubstituted phenoxyacetamides under the action of trifluoromethanesulfonic anhydride in the presence of 2-fluoropyridine in methylene chloride at room temperature. The proposed novel and efficient protocol has been successfully utilized to obtain a wide series of 3-amino-1-benzofurans with various substituents in the benzene ring and amino group.

  DOI：

  10.1134/s1070428019090173

文献信息

• [EN] CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS<br/>[FR] COMPOSÉS CHIMIQUES UTILISÉS COMME INHIBITEURS DE LA VOIE ATF4
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017212425A1

  公开（公告）日：2017-12-14

  The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及替代哌啶衍生物。具体而言，该发明涉及符合以下式III的化合物：其中A、B、X、Y、L1、L2、L3、R1、R2、R3、R4、R5、R6、R9、z2、z4、z5和z6如本文所定义，并其盐。该发明的化合物是ATF4途径的抑制剂，可用于治疗癌症、癌前综合征以及与激活的未折叠蛋白应答途径相关的疾病，如阿尔茨海默病、脊髓损伤、创伤性脑损伤、缺血性中风、中风、糖尿病、帕金森病、亨廷顿病、克雅氏病及相关朊蛋白病、进行性核上性麻痹、肌萎缩侧索硬化、心肌梗死、心血管疾病、炎症、纤维化、肝脏慢性和急性疾病、肺部慢性和急性疾病、肾脏慢性和急性疾病、慢性创伤性脑病（CTE）、神经退行性疾病、痴呆、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官移植运输。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制ATF4途径和治疗相关疾病的方法。